Literature DB >> 10934169

Loss of p53 promotes anaplasia and local invasion in ret/PTC1-induced thyroid carcinomas.

K M La Perle1, S M Jhiang, C C Capen.   

Abstract

Papillary thyroid carcinomas in humans are associated with the ret/PTC oncogene and, following loss of p53 function, may progress to anaplastic carcinomas. Mice with thyroid-targeted expression of ret/PTC1 developed papillary thyroid carcinomas that were minimally invasive and did not metastasize. These mice were crossed with p53-/- mice to investigate whether loss of p53 would promote anaplasia and metastasis of ret/PTC1-induced thyroid tumors. The majority of p53-/- mice died or were euthanized by 17 weeks of age due to the development of thymic lymphomas, soft tissue sarcomas, and testicular teratomas. All ret/PTC1 mice developed thyroid carcinomas, but tumors in p53-/- mice were more anaplastic, larger in diameter, more invasive, and had a higher mitotic index than tumors in p53+/+ and p53+/- mice. Thyroid tumors did not metastasize in any of the experimental p53+/+ and p53+/- mice </=28 weeks of age or p53-/- mice </= 17 weeks of age; however, an older (170-day-old) male p53-/- mouse used to maintain the colony developed anaplastic thyroid carcinoma with liver metastases. These findings demonstrate that the lack of functional p53 in ret/PTC1 mice promotes anaplasia and invasiveness of thyroid carcinomas.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10934169      PMCID: PMC1850128          DOI: 10.1016/S0002-9440(10)64577-4

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  40 in total

1.  Reexpression of thyroid peroxidase in a derivative of an undifferentiated thyroid carcinoma cell line by introduction of wild-type p53.

Authors:  J A Fagin; S H Tang; K Zeki; R Di Lauro; A Fusco; R Gonsky
Journal:  Cancer Res       Date:  1996-02-15       Impact factor: 12.701

2.  Tumour incidence, spectrum and ploidy in mice with a large deletion in the p53 gene.

Authors:  C A Purdie; D J Harrison; A Peter; L Dobbie; S White; S E Howie; D M Salter; C C Bird; A H Wyllie; M L Hooper
Journal:  Oncogene       Date:  1994-02       Impact factor: 9.867

3.  Differentiated carcinomas develop as a consequence of the thyroid specific expression of a thyroglobulin-human papillomavirus type 16 E7 transgene.

Authors:  C Ledent; A Marcotte; J E Dumont; G Vassart; M Parmentier
Journal:  Oncogene       Date:  1995-05-04       Impact factor: 9.867

4.  Retinoblastoma and p53 tumour suppressor gene protein expression in carcinomas of the thyroid gland.

Authors:  R Holm; J M Nesland
Journal:  J Pathol       Date:  1994-03       Impact factor: 7.996

5.  Spontaneous and carcinogen-induced tumorigenesis in p53-deficient mice.

Authors:  M Harvey; M J McArthur; C A Montgomery; J S Butel; A Bradley; L A Donehower
Journal:  Nat Genet       Date:  1993-11       Impact factor: 38.330

6.  Stepwise participation of p53 gene mutation during dedifferentiation of human thyroid carcinomas.

Authors:  Y Dobashi; H Sugimura; A Sakamoto; M Mernyei; M Mori; T Oyama; R Machinami
Journal:  Diagn Mol Pathol       Date:  1994-03

7.  Production of transgenic mice expressing the Ki-ras oncogene under the control of a thyroglobulin promoter.

Authors:  G Santelli; V de Franciscis; G Portella; G Chiappetta; A D'Alessio; D Califano; R Rosati; A Mineo; C Monaco; G Manzo
Journal:  Cancer Res       Date:  1993-11-15       Impact factor: 12.701

8.  Oncogenic potential of guanine nucleotide stimulatory factor alpha subunit in thyroid glands of transgenic mice.

Authors:  F M Michiels; B Caillou; M Talbot; F Dessarps-Freichey; M T Maunoury; M Schlumberger; L Mercken; R Monier; J Feunteun
Journal:  Proc Natl Acad Sci U S A       Date:  1994-10-25       Impact factor: 11.205

9.  p53 expression in anaplastic carcinomas arising from thyroid papillary carcinomas.

Authors:  X Matias-Guiu; M Cuatrecasas; E Musulen; J Prat
Journal:  J Clin Pathol       Date:  1994-04       Impact factor: 3.411

10.  Tumor spectrum analysis in p53-mutant mice.

Authors:  T Jacks; L Remington; B O Williams; E M Schmitt; S Halachmi; R T Bronson; R A Weinberg
Journal:  Curr Biol       Date:  1994-01-01       Impact factor: 10.834

View more
  24 in total

1.  Antisense p53 decreases production of VEGF in follicular thyroid cancer cells.

Authors:  I Hassan; A Wunderlich; E Slater; S Hoffmann; I Celik; A Zielke
Journal:  Endocrine       Date:  2006-06       Impact factor: 3.633

Review 2.  Mutation-associated fusion cancer genes in solid tumors.

Authors:  Frederic J Kaye
Journal:  Mol Cancer Ther       Date:  2009-06-09       Impact factor: 6.261

Review 3.  Anaplastic thyroid cancer, tumorigenesis and therapy.

Authors:  J P O'Neill; D Power; C Condron; D Bouchier-Hayes; M Walsh
Journal:  Ir J Med Sci       Date:  2009-08-07       Impact factor: 1.568

4.  Mouse Model of Thyroid Cancer Progression and Dedifferentiation Driven by STRN-ALK Expression and Loss of p53: Evidence for the Existence of Two Types of Poorly Differentiated Carcinoma.

Authors:  Alyaksandr V Nikitski; Susan L Rominski; Vincenzo Condello; Cihan Kaya; Mamta Wankhede; Federica Panebianco; Hong Yang; Daniel L Altschuler; Yuri E Nikiforov
Journal:  Thyroid       Date:  2019-08-16       Impact factor: 6.568

Review 5.  Modulation of sodium iodide symporter in thyroid cancer.

Authors:  Aparna Lakshmanan; Daniel Scarberry; Daniel H Shen; Sissy M Jhiang
Journal:  Horm Cancer       Date:  2014-09-19       Impact factor: 3.869

Review 6.  Lessons from mouse models of thyroid cancer.

Authors:  Caroline S Kim; Xuguang Zhu
Journal:  Thyroid       Date:  2009-12       Impact factor: 6.568

7.  Villous papillary thyroid carcinoma: a variant associated with marfan syndrome.

Authors:  Daniel A Winer; Shawn Winer; Lorne Rotstein; Sylvia L Asa; Ozgur Mete
Journal:  Endocr Pathol       Date:  2012-12       Impact factor: 3.943

8.  Animal models of cancer in the head and neck region.

Authors:  Seungwon Kim
Journal:  Clin Exp Otorhinolaryngol       Date:  2009-06-27       Impact factor: 3.372

9.  Up-regulation of transcriptional factor E2F1 in papillary and anaplastic thyroid cancers.

Authors:  Masamitsu Onda; Hisaki Nagai; Akira Yoshida; Shizuyo Miyamoto; Shin-Ichi Asaka; Junko Akaishi; Keisuke Takatsu; Mitsuji Nagahama; Kouichi Ito; Kazuo Shimizu; Mitsuru Emi
Journal:  J Hum Genet       Date:  2004-04-29       Impact factor: 3.172

Review 10.  Modeling thyroid cancer in the mouse.

Authors:  X-G Zhu; S-Y Cheng
Journal:  Horm Metab Res       Date:  2009-04-08       Impact factor: 2.936

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.